A Pillar Of Eisai’s Growth Strategy Misses Primary Endpoint In First Phase III Trial
This article was originally published in PharmAsia News
Eisai-acquired Morphotek lead candidate farletuzumab sees disappointing results in platinum-sensitive ovarian cancer.
You may also be interested in...
Efficacy results were not uniformly positive in pivotal trials of newly approved perampanel, but FDA explains that may be due to high placebo rates in some international sites.
Even though Eisai’s Halaven showed an unprecedented overall survival effect in a very tough-to-treat breast cancer population, the drug appears to have flopped in a head-to-head study against Xeloda in an earlier line of therapy. Nevertheless, Eisai vows to pursue a regulatory filing that would expand the drug’s label, as planned.
Merck will acquire rights to develop and commercialize Endocyte’s vintafolide, in Phase III development for ovarian cancer, in exchange for $120 million upfront and up to $880 million in milestones.